@The Yankee
Always good to read your posts.
I remember the video well and you are correct the key here is approval. The other key is to maintain product pricing to reflect innovation and not be devalued.
In time price will come down and I trust SI will not sell the company short. With the holding he has and the time he has invested there is no way he will do that.
Our niche and primary aim is rare life threatening disease for unmet needs. Treating cytokine storm syndrome in severe life threatening cases in Covid would be a huge bonus but not at discounted pricing. The key is to find the niche here and treat the most severe cases where other treatments fail and maintain our price.
SI has always said MSCs work best in the most severe cases.
I will be most interested to see how we price Ryoncil. Any reasearch on pricing from the board would be great.
Silviu Itescu and the Vatican, page-7
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |